EE+ POEM Archive
Lecanemab does not significantly improve cognition in early Alzheimer's disease, is expensive, and causes brain edema and hemorrhage in some patients
Lecanemab does not significantly improve cognition in early Alzheimer's disease, is expensive, and causes brain edema and hemorrhage in some patients is a topic covered in the EE+ POEM Archive.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "Lecanemab Does Not Significantly Improve Cognition in Early Alzheimer's Disease, Is Expensive, and Causes Brain Edema and Hemorrhage in some Patients." EE+ POEM Archive, John Wiley & Sons, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315783/all/Lecanemab_does_not_significantly_improve_cognition_in_early_Alzheimer's_disease__is_expensive__and_causes_brain_edema_and_hemorrhage_in_some_patients.
Lecanemab does not significantly improve cognition in early Alzheimer's disease, is expensive, and causes brain edema and hemorrhage in some patients. In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2019. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315783/all/Lecanemab_does_not_significantly_improve_cognition_in_early_Alzheimer's_disease__is_expensive__and_causes_brain_edema_and_hemorrhage_in_some_patients. Accessed March 29, 2023.
Lecanemab does not significantly improve cognition in early Alzheimer's disease, is expensive, and causes brain edema and hemorrhage in some patients. (2019). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315783/all/Lecanemab_does_not_significantly_improve_cognition_in_early_Alzheimer's_disease__is_expensive__and_causes_brain_edema_and_hemorrhage_in_some_patients
Lecanemab Does Not Significantly Improve Cognition in Early Alzheimer's Disease, Is Expensive, and Causes Brain Edema and Hemorrhage in some Patients [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2019. [cited 2023 March 29]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315783/all/Lecanemab_does_not_significantly_improve_cognition_in_early_Alzheimer's_disease__is_expensive__and_causes_brain_edema_and_hemorrhage_in_some_patients.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Lecanemab does not significantly improve cognition in early Alzheimer's disease, is expensive, and causes brain edema and hemorrhage in some patients
ID - 1315783
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315783/all/Lecanemab_does_not_significantly_improve_cognition_in_early_Alzheimer's_disease__is_expensive__and_causes_brain_edema_and_hemorrhage_in_some_patients
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
